WILBERT

Wildauer Bücher+E-Medien Recherche-Tool

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Collection
Keywords
Language
  • 1
    Online Resource
    Online Resource
    Global Institute of Pharmaceutical Education and Research
    free Journals Online: 1(1)2016 – (Go to Journal)
    Publisher: Global Institute of Pharmaceutical Education and Research
    Electronic ISSN: 2456-8058
    Topics: Chemistry and Pharmacology
    Keywords: Pharmazie
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    facet.materialart.
    facet.materialart.
    Jena: Univ. [u.a.]
    Publication Date: 2012-04-12
    Description: In this paper we focus on proximity as one of the main determinants of international collaboration in pharmaceutical research. We use various count data specifications of the gravity model to estimate the intensity of collaboration between pairs of countries as explained by the geographical, cognitive, institutional, social, and cultural dimensions of proximity. Our results suggest that geographical distance has a significant negative relation to the collaboration intensity between countries. The amount of previous collaborations, as a proxy for social proximity, is positively related to the number of cross-country collaborations. We do not find robust significant associations between cognitive proximity or institutional proximity with the intensity of international research collaboration. Moreover, there is no robust and significant relation between the interaction terms of geographical distance with social, cognitive, or institutional proximity, and international research collaboration. Our findings for cultural proximity do not allow of unambiguous conclusions concerning their influence on the collaboration intensity between countries. Linguistic ties among countries are associated with a higher amount of cross-country research collaboration but we find no clear association for historical and colonial linkages.
    Keywords: R10 ; O31 ; ddc:330 ; international cooperation ; pharmaceuticals ; proximity ; Pharmazeutische Forschung ; Forschungskooperation ; Unternehmenskooperation ; Entfernung ; Schätzung ; Welt
    Language: English
    Type: doc-type:workingPaper
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    facet.materialart.
    facet.materialart.
    Helsinki: The United Nations University World Institute for Development Economics Research (UNU-WIDER)
    Publication Date: 2018-11-16
    Description: A comparative study is undertaken that explores Chinese and Indian pharmaceutical industries under different patent regimes. It is found that relative to India, which had implemented process patent until 2005, China with a product patent regime since 1993 suffers from both lower drug accessibility and availability (the latter is a missing parameter in the literature). Also, China lags behind in both lower R&D investment and patents filed by Chinese nationals. Based on these findings and associated legal interpretation, we conclude that higher patent protection in China generates negative impacts on the pharmaceutical industries. Thus, governments should utilize TRIPS flexibilities and other regimes like price control to offset the anticompetitive effect in designing patent policies.
    Keywords: O34 ; L65 ; F14 ; ddc:330 ; product patent ; process patent ; TRIPS ; pharmaceutical industries ; China ; India ; TRIPS ; Patentrecht ; Wohlfahrtseffekt ; Pharmazeutische Industrie ; China ; Indien
    Language: English
    Type: doc-type:workingPaper
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    facet.materialart.
    facet.materialart.
    Stockholm: The Research Institute of Industrial Economics (IUI)
    Publication Date: 2014-11-17
    Description: We consider policy issues regarding parallel imports (PIs) of brand-name pharmaceuticals in the European Union, where such trade is permitted. We develop a simple model in which an original manufacturer competes in its home market with PI firms. The model suggests that for small trade costs the original manufacturer will accommodate the import decisions of parallel traders and that the price in the home market falls as the volume of parallel imports rises. Using data from Sweden we find that the prices of drugs subject to competition from parallel imports fell relative to other drugs over the period 1994 - 1999. Econometric analysis finds that parallel imports significantly reduced manufacturing prices, by from 12 to 19 percent. There is evidence that this effect increases with multiple PI entrants.
    Keywords: F12 ; I11 ; L12 ; ddc:330 ; Parallel Imports ; International Arbitrage ; Drug Pricing ; Pharmaceutical Products ; Pharmazeutisches Produkt ; Betriebliche Preispolitik ; Import ; EU-Staaten ; Grauer Markt
    Language: English
    Type: doc-type:workingPaper
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    facet.materialart.
    facet.materialart.
    Mannheim: Zentrum für Europäische Wirtschaftsforschung (ZEW)
    Publication Date: 2013-05-22
    Description: On April 1, 2005, Denmark changed the way references prices, a main determinant of reimbursements for pharmaceutical purchases, are calculated. The previous reference prices, which were based on average EU prices, were substituted to minimum domestic prices. Novel to the literature, we estimate the joint effects of this reform on prices and quantities. Prices decreased more than 26 percent due to the reform, which reduced patient and government expenditures by 3.0 percent and 5.6 percent, respectively, and producer revenues by 5.0 percent. The prices of expensive products decreased more than their cheaper counterparts, resulting in large differences in patient benefits from the reform.
    Keywords: I18 ; C23 ; ddc:330 ; pharmaceutical markets ; regulation ; co-payments ; reference pricing ; asymmetric welfare effects ; Pharmazeutische Industrie ; Regulierung ; Pharmazeutisches Produkt ; Preis ; Wohlfahrtseffekt ; Dänemark
    Language: English
    Type: doc-type:workingPaper
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    facet.materialart.
    facet.materialart.
    Bonn: Institute for the Study of Labor (IZA)
    Publication Date: 2018-11-15
    Description: Reference prices constitute a main determinant of patient health care reimbursement in many countries. We study the effects of a change from an external (based on a basket of prices in other countries) to an internal (based on comparable domestic products) reference price system. We find that while our estimated consumer compensating variation is small, the reform led to substantial reductions in list and reference prices as well as co-payments, and to sizeable decreases in overall producer revenues, health care expenditures, and co-payments. These effects differ markedly between branded drugs, generics, and parallel imports with health care expenditures and producer revenues decreasing and co-payments increasing most for branded drugs. The reform also induced consumers to substitute from branded drugs - for which they have strong preferences - to generics and parallel imports. This substitution also explains the small increase in consumer welfare despite a substantial decrease in expenditures.
    Keywords: I18 ; C23 ; ddc:330 ; pharmaceutical markets ; regulation ; co-payments ; reference pricing ; welfare effects
    Language: English
    Type: doc-type:workingPaper
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    facet.materialart.
    facet.materialart.
    Publication Date: 2017-09-25
    Description: Does life have a different price according to the country where people are born? Should there be a customized definition of ethics in function of the country where clinical trials are being carried on? The actual international regulatory environment proves to be inadequate to guarantee a fair treatment of patients involved in drug trials around the world, a situation which is proven by the case of India. The incapacity of Indian national regulators to efficiently monitor trials and enforce the law, as well as the increasing use of outsourcing in clinical trials gives place to abuse of patients’ rights in the name of science or for corporate profits. The article aspires to make a modest contribution to this field by analyzing to what extent pharmaceutical companies are interested in perpetuating the diffuse area around the responsibility and ethics of drug trials in developing countries. Moreover, it offers suggestions as to how they can improve their CSR practices.
    Keywords: ddc:330
    Language: English
    Type: article , doc-type:article
    Format: application/pdf
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    facet.materialart.
    facet.materialart.
    Kiel und Hamburg: ZBW - Deutsche Zentralbibliothek für Wirtschaftswissenschaften, Leibniz-Informationszentrum Wirtschaft
    Publication Date: 2015-02-17
    Description: Reference prices constitute a main determinant of patient health care reimbursement in many countries. We study the effects of a change from an "external" (based on a basket of prices in other countries) to an "internal" (based on comparable domestic products) reference price system. We find that while our estimated consumer compensating variation is small, the reform led to substantial reductions in list and reference prices as well as co-payments, and to sizeable decreases in overall producer revenues, health care expenditures, and co-payments. These effects differ markedly between branded drugs, generics, and parallel imports with health care expenditures and producer revenues decreasing and co-payments increasing most for branded drugs. The reform also induced consumers to substitute from branded drugs - for which they have strong preferences - to generics and parallel imports. This substitution also explains the small increase in consumer welfare despite a substantial decrease in expenditures.
    Keywords: I18 ; C23 ; D22 ; ddc:330
    Language: English
    Type: doc-type:conferenceObject
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    facet.materialart.
    facet.materialart.
    Geneva: United Nations Research Institute for Social Development (UNRISD)
    Publication Date: 2017-01-11
    Description: To address problems of inadequate public health services, escalating private healthcare costs and widening health inequalities, the South African government has launched a radical new proposal to introduce a universal health system for all South Africans; National Health Insurance (NHI). While most attention has been thus far devoted to the economics and fiscal affordability of universal coverage, relatively less attention has been paid to wider challenges - in particular the important role played by key stakeholders tasked with designing and implementing the reforms. This paper outlines the opportunities and challenges posed by the proposed NHI reforms in South Africa. It begins by explaining the country´s current system of health care provision including its human resource structure, functions and cost implications. It then summarizes the deficits and limitations of the current two-tiered health system and discusses what NHI is trying to achieve within this context and how it hopes to address the problems. Finally, the paper examines the political and institutional challenges the reforms will face with a particular focus on the actors involved. The findings suggest that the government will face considerable challenges to its proposed reform path and that the eventual design of the new system may have to be a compromised version of the system envisaged in the original Green Paper. In particular the government will face significant challenges in garnering the support of sections of the medical profession tasked with implementing the reforms.
    Keywords: ddc:330
    Language: English
    Type: doc-type:workingPaper
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    facet.materialart.
    facet.materialart.
    Geneva: United Nations Research Institute for Social Development (UNRISD)
    Publication Date: 2017-01-11
    Description: Healthcare in Russia has gone through many transformative stages, from a Soviet-era model of public provision to an emphasis on privatization under economic liberalization during the 1990s. Both have legacies that survive to the present, and now a mix of both public and private healthcare provision operates across Russia. Throughout all these periods, universalism has been enshrined as a guarantee, at least nominally. The extent to which this right has been upheld varies greatly, with some major constraints to universal provision in Russia. Underfinancing presents a persistent obstacle to universal access, and substantial inequalities in healthcare access and quality exist across different regions and income groups, with some vulnerable and marginalized groups left almost entirely excluded. Furthermore, despite efforts to improve quality and provision of healthcare, Russia has a poor record in many health indicators, and its national system is struggling to become more efficient and effective.
    Keywords: ddc:330
    Language: English
    Type: doc-type:workingPaper
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...